NCT03215277

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 76 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).

Conditions

• Ankylosing Spondylitis

Interventions

Type	Name	Description
DRUG	Bimekizumab	One bimekizumab dose will be administered.
DRUG	Certolizumab pegol	Two certolizumab pegol doses will be administered. One of these doses is a loading dose.
OTHER	Placebo	Placebo will be provided to maintain the blinding.

Timeline

• Start date: 2017-10-04
• Primary completion: 2020-05-25
• Completion: 2020-05-25
• First posted: 2017-07-12
• Last updated: 2023-07-27
• Results posted: 2023-07-27

Locations

34 sites across 8 countries: United States, Czechia, Germany, Greece, Moldova, Netherlands, Poland, Russia

Regulatory

• FDA-regulated drug study